Astex Pharmaceuticals

astx.com

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

TO PROVIDE SUITE OF CLINICAL TRIAL TECHNOLOGIES AND SERVICES, LABCORP RENEWED STRATEGIC PARTNERSHIP WITH MEDIDATA

Medidata | April 01, 2022

news image

A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentr...

Read More

Pharma Tech

SUMITOVANT BIOPHARMA AND SUMITOMO PHARMA ANNOUNCE OFFER TO ACQUIRE OUTSTANDING SHARES OF MYOVANT SCIENCES

Sumitovant Biopharma Ltd. | October 03, 2022

news image

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash. The proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange. The proposed acquisition consideration repres...

Read More

Pharma Tech

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

news image

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More

PHARMACY MARKET

BIOFOURMIS ACCELERATES AND SIMPLIFIES DRUG DEVELOPMENT WITH EXPANDED DIGITAL CLINICAL TRIALS SOLUTION

PR Newswire | September 21, 2023

news image

Biofourmis, a leading global technology-enabled care delivery company, announced today the release of its expanded Digital Clinical Trials solution within the Biofourmis platform for biopharma and other life sciences companies. The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity wh...

Read More
news image

Business Insights

TO PROVIDE SUITE OF CLINICAL TRIAL TECHNOLOGIES AND SERVICES, LABCORP RENEWED STRATEGIC PARTNERSHIP WITH MEDIDATA

Medidata | April 01, 2022

A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentr...

Read More
news image

Pharma Tech

SUMITOVANT BIOPHARMA AND SUMITOMO PHARMA ANNOUNCE OFFER TO ACQUIRE OUTSTANDING SHARES OF MYOVANT SCIENCES

Sumitovant Biopharma Ltd. | October 03, 2022

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash. The proposed transaction, if completed, would result in Myovant being delisted from the New York Stock Exchange. The proposed acquisition consideration repres...

Read More
news image

Pharma Tech

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More
news image

PHARMACY MARKET

BIOFOURMIS ACCELERATES AND SIMPLIFIES DRUG DEVELOPMENT WITH EXPANDED DIGITAL CLINICAL TRIALS SOLUTION

PR Newswire | September 21, 2023

Biofourmis, a leading global technology-enabled care delivery company, announced today the release of its expanded Digital Clinical Trials solution within the Biofourmis platform for biopharma and other life sciences companies. The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity wh...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us